ARCHIVES

Vectibix Non-Inferior to Erbitux In Wild-Type Metastatic Disease

This article is from The Cancer Letter archive.

Vol. 36 No. 10 | October 25, 2013

Download PDF Visit The Full Archive

Related Articles

Radiation Doesn’t Add Benefit For Early Endometrial Cancer

June 29, 2007

Perjeta, Herceptin & Docetaxel Combination Extended Survival in HER2-Positive Disease

December 28, 2012

SAIC Frederick Offers Use Of Drug Facility

August 4, 1995

Doctor’s Allegation Of Drug Safety Problem Starts Controversy With Manufacturer

May 5, 1995

NCI Offers Informations, Resources, To Industry.

April 6, 2001

M.D. Anderson Closes Trials following FDA Requests for Data

February 16, 1996